{
    "clinical_study": {
        "@rank": "61", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of glufosfamide in treating patients who\n      have recurrent glioblastoma multiforme."
        }, 
        "brief_title": "Glufosfamide in Treating Patients With Recurrent Glioblastoma Multiforme", 
        "condition": "Brain and Central Nervous System Tumors", 
        "condition_browse": {
            "mesh_term": [
                "Glioblastoma", 
                "Nervous System Neoplasms", 
                "Central Nervous System Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Determine the activity of glufosfamide, in terms of objective response rate\n      and/or progression-free survival at 6 months, in patients with recurrent glioblastoma\n      multiforme. II. Determine the duration of objective response in patients treated with this\n      regimen. III. Determine the toxic effects and pharmacokinetic profile of this regimen in\n      these patients.\n\n      OUTLINE: This is a multicenter study. Patients receive glufosfamide IV over 60 minutes on\n      day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable\n      toxicity. Patients with stable disease receive treatment for a minimum of 6 months or until\n      progression. Patients with an objective complete response receive a maximum of 2 additional\n      courses of treatment after confirmation of response. Patients are followed every 6 weeks\n      until progression.\n\n      PROJECTED ACCRUAL: A total of 28 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed glioblastoma multiforme\n        Recurrent disease by CT scan or MRI At least 1 bidimensionally measurable target lesion at\n        least 2 cm in the largest diameter\n\n        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n        least 3 months Hematopoietic: Neutrophil count at least 1,500/mm3 Platelet count at least\n        100,000/mm3 Hepatic: Bilirubin less than 1.5 times upper limit of normal (ULN) Alkaline\n        phosphatase no greater than 2.5 times ULN AST and ALT no greater than 2.5 times ULN Renal:\n        Creatinine no greater than 1.5 mg/dL Creatinine clearance at least 60 mL/min\n        Cardiovascular: Cardiac function normal No history of ischemic heart disease within the\n        past 6 months 12 lead ECG normal Other: No other prior or concurrent malignancy except\n        cone biopsied cervical cancer or adequately treated basal cell or squamous cell skin\n        cancer No unstable systemic disease No active uncontrolled infection No psychological,\n        familial, sociological, or geographical condition that would preclude study Not pregnant\n        or nursing Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent prophylactic growth factors\n        (e.g., filgrastim (G-CSF)) Chemotherapy: No more than 1 prior chemotherapy regimen as\n        adjuvant therapy or for recurrent disease At least 6 weeks since prior chemotherapy\n        Endocrine therapy: Stable or decreasing dose of corticosteroids for at least 1 week prior\n        to study Radiotherapy: At least 3 months since prior radiotherapy to the brain No prior\n        high-dose radiotherapy (more than 65 Gy), stereotactic radiosurgery, or internal\n        radiotherapy unless the disease recurrence is histologically confirmed Surgery: No prior\n        surgery (except biopsy) for recurrent brain tumor At least 3 months since prior surgery\n        for primary brain tumor Other: No other concurrent anticancer agents No other concurrent\n        investigational agents"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 10, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00014300", 
            "org_study_id": "EORTC-16994G-26002", 
            "secondary_id": "EORTC-16994G-26002"
        }, 
        "intervention": {
            "intervention_name": "glufosfamide", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Ifosfamide"
        }, 
        "keyword": [
            "recurrent adult brain tumor", 
            "adult glioblastoma", 
            "adult giant cell glioblastoma", 
            "adult gliosarcoma"
        ], 
        "lastchanged_date": "September 20, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/EORTC-16994G-26002"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Vienna (Wien)", 
                        "country": "Austria", 
                        "zip": "A-1100"
                    }, 
                    "name": "Kaiser Franz Josef Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clermont-Ferrand", 
                        "country": "France", 
                        "zip": "63011"
                    }, 
                    "name": "Centre Jean Perrin"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dijon", 
                        "country": "France", 
                        "zip": "21079"
                    }, 
                    "name": "Centre de Lute Contre le Cancer,Georges-Francois Leclerc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "zip": "69373"
                    }, 
                    "name": "Centre Leon Berard"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nantes-Saint Herblain", 
                        "country": "France", 
                        "zip": "44805"
                    }, 
                    "name": "CRLCC Nantes - Atlantique"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nice", 
                        "country": "France", 
                        "zip": "06189"
                    }, 
                    "name": "Centre Antoine Lacassagne"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75651"
                    }, 
                    "name": "CHU Pitie-Salpetriere"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rennes", 
                        "country": "France", 
                        "zip": "35064"
                    }, 
                    "name": "Centre Eugene Marquis"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif", 
                        "country": "France", 
                        "zip": "F-94805"
                    }, 
                    "name": "Institut Gustave Roussy"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ioannina", 
                        "country": "Greece", 
                        "zip": "GR-45110"
                    }, 
                    "name": "University of Ioannina"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Petah-Tikva", 
                        "country": "Israel", 
                        "zip": "49202"
                    }, 
                    "name": "Schneider Children's Medical Center of Israel"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Padova (Padua)", 
                        "country": "Italy", 
                        "zip": "35128"
                    }, 
                    "name": "Azienda Ospedaliera di Padova"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rome", 
                        "country": "Italy", 
                        "zip": "00161"
                    }, 
                    "name": "Istituti Fisioterapici Ospitalieri - Roma"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "3075 EA"
                    }, 
                    "name": "Rotterdam Cancer Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Utrecht", 
                        "country": "Netherlands", 
                        "zip": "3508 GA"
                    }, 
                    "name": "Academisch Ziekenhuis Utrecht"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lisbon", 
                        "country": "Portugal", 
                        "zip": "1093"
                    }, 
                    "name": "Instituto Portugues de Oncologia de Francisco Gentil"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lausanne", 
                        "country": "Switzerland", 
                        "zip": "CH-1011"
                    }, 
                    "name": "Centre Hospitalier Universitaire Vaudois"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Gallen", 
                        "country": "Switzerland", 
                        "zip": "CH-9007"
                    }, 
                    "name": "Kantonsspital - St. Gallen"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "France", 
                "Greece", 
                "Israel", 
                "Italy", 
                "Netherlands", 
                "Portugal", 
                "Switzerland"
            ]
        }, 
        "official_title": "Open Label Phase II Study On Glufosfamide Administered As A 60 Minute Infusion Every 3 Weeks In Recurrent Glioblastoma Multiforme", 
        "overall_official": {
            "affiliation": "Daniel Den Hoed Cancer Center at Erasmus Medical Center", 
            "last_name": "Martin J. van Den Bent, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2001", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00014300"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "European Organisation for Research and Treatment of Cancer - EORTC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "European Organisation for Research and Treatment of Cancer - EORTC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2001", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }, 
    "geocoordinates": {
        "Academisch Ziekenhuis Utrecht": "52.09 5.11", 
        "Azienda Ospedaliera di Padova": "45.41 11.877", 
        "CHU Pitie-Salpetriere": "48.857 2.352", 
        "CRLCC Nantes - Atlantique": "47.21 -1.602", 
        "Centre Antoine Lacassagne": "43.696 7.266", 
        "Centre Eugene Marquis": "48.113 -1.676", 
        "Centre Hospitalier Universitaire Vaudois": "46.52 6.634", 
        "Centre Jean Perrin": "45.777 3.087", 
        "Centre Leon Berard": "45.764 4.836", 
        "Centre de Lute Contre le Cancer,Georges-Francois Leclerc": "47.322 5.041", 
        "Institut Gustave Roussy": "48.793 2.359", 
        "Instituto Portugues de Oncologia de Francisco Gentil": "38.707 -9.136", 
        "Istituti Fisioterapici Ospitalieri - Roma": "41.891 12.494", 
        "Kaiser Franz Josef Hospital": "48.208 16.374", 
        "Kantonsspital - St. Gallen": "47.424 9.371", 
        "Rotterdam Cancer Institute": "51.924 4.482", 
        "Schneider Children's Medical Center of Israel": "32.084 34.888", 
        "University of Ioannina": "39.674 20.84"
    }
}